M. Noman

发表

Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease

S. Vermeire, G. D'Haens, M. Ferrante, 2012, Inflammatory bowel diseases.

Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease

P. Rutgeerts, M. Noman, J. Ceuppens, 2002, American Journal of Gastroenterology.

Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort

K. Van Steen, P. Rutgeerts, S. Vermeire, 2008, Gut.

Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease.

P. Rutgeerts, S. Vermeire, M. Ferrante, 2009, Gastroenterology.

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.

P. Rutgeerts, S. Vermeire, W. Robberecht, 2005, The New England journal of medicine.

Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease

J. Belaiche, P. Rutgeerts, A. Gossum, 2002, American Journal of Gastroenterology.

Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn’s Disease and Ulcerative Colitis

P. Rutgeerts, S. Vermeire, M. Ferrante, 2017, Journal of Crohn's & colitis.

The impact of major depressive disorder on the short‐ and long‐term outcome of Crohn's disease treatment with infliximab

P. Rutgeerts, S. Vermeire, K. Demyttenaere, 2005, Alimentary pharmacology & therapeutics.

T1209 New Mechanism of Action for Anti-TNF Therapy in IBD: Induction of FOXP3+CD4+CD25+ and FOXP3+CD4+CD25- T Cells in Crohn's Disease and Ulcerative Colitis

P. Rutgeerts, S. Vermeire, M. Noman, 2008 .

Identifying predictors of low adherence in patients with inflammatory bowel disease

S. Vermeire, M. Ferrante, M. Noman, 2016, European journal of gastroenterology & hepatology.

Hyperresponsiveness of the Mucosal Barrier in Crohn's Disease Is Not Tumor Necrosis Factor‐Dependent

P. Rutgeerts, S. Vermeire, M. Noman, 2005, Inflammatory bowel diseases.

Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease

J. Belaiche, P. Rutgeerts, A. Gossum, 2002, American Journal of Gastroenterology.

MANAGEMENT OF ULCERATIVE COLITIS AND CROHN’S DISEASE

P. Rutgeerts, S. Vermeire, G. D'Haens, 2004, Acta clinica Belgica.

Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study

P. Rutgeerts, S. Vermeire, M. Ferrante, 2007, Gut.

Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease.

K. Van Steen, P. Rutgeerts, S. Vermeire, 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Corticosteroids but not infliximab increase short‐term postoperative infectious complications in patients with ulcerative colitis

P. Rutgeerts, S. Vermeire, M. Ferrante, 2009, Inflammatory bowel diseases.

Restoration of Foxp3+ Regulatory T-cell Subsets and Foxp3− Type 1 Regulatory-like T Cells in Inflammatory Bowel Diseases During Anti-tumor Necrosis Factor Therapy

K. Van Steen, P. Rutgeerts, S. Vermeire, 2015, Inflammatory bowel diseases.

Ustekinumab exposure-outcome analysis in Crohn's disease only in part explains limited endoscopic remission rates.

S. Vermeire, A. Gils, M. Ferrante, 2019, Journal of Crohn's & colitis.

CROHN’S DISEASE WHO FAILED BIOLOGIC THERAPIES: A NATIONAL COHORT STUDY

M. Vos, S. Vermeire, E. Louis, 2020 .

Long-term clinical effectiveness of ustekinumab in patients with Crohn's disease who failed biological therapies: a national cohort study.

D. Franchimont, S. Vermeire, E. Louis, 2019, Journal of Crohn's & colitis.

Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial

P. Rutgeerts, G. D'Haens, M. Noman, 2001, American Journal of Gastroenterology.

Etanercept in the treatment of active refractory Crohn’s disease: a single-center pilot trial

P. Rutgeerts, G. D'Haens, M. Noman, 2001 .

The risk of post‐operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study

P. Rutgeerts, S. Vermeire, G. D'Haens, 2004, Alimentary pharmacology & therapeutics.

Influence of drug exposure on vedolizumab-induced endoscopic remission in anti-TNF naïve and anti-TNF exposed IBD patients.

S. Vermeire, A. Gils, M. Ferrante, 2020, Journal of Crohn's & colitis.

Mucosal Healing and Long‐term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic‐Based vs Trough Concentration‐Based Dosing of Infliximab

P. Rutgeerts, S. Vermeire, A. Gils, 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy

K. Van Steen, P. Rutgeerts, S. Vermeire, 2011, Inflammatory bowel diseases.

Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study.

K. Van Steen, P. Rutgeerts, S. Vermeire, 2003, Gastroenterology.

Effects of Education and Information on Vaccination Behavior in Patients with Inflammatory Bowel Disease

S. Vermeire, M. Ferrante, M. Noman, 2017, Inflammatory bowel diseases.

Intravenous iron therapy restores functional iron deficiency induced by infliximab.

P. Rutgeerts, S. Vermeire, M. Ferrante, 2007, Journal of Crohn's & colitis.

Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease.

J. Belaiche, P. Rutgeerts, A. Gossum, 2002 .

Recombinant soluble p55 TNF receptor induces remission, is non-immunogenic and well tolerated in active Crohn's disease: Results of a randomized pilot trial

P. Rutgeerts, M. Noman, G. Assche, 2001 .

A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis.

P. Rutgeerts, S. Vermeire, A. Gils, 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

nfluence of Trough Serum Levels and Immunogenicity on Long-term utcome of Adalimumab Therapy in Crohn ’ s Disease

P. Rutgeerts, S. Vermeire, M. Noman, 2013 .

Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial.

P. Rutgeerts, S. Vermeire, G. D'Haens, 2005, Gastroenterology.

Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial

P. Rutgeerts, S. Vermeire, A. Gils, 2011, Gut.

Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.

P. Rutgeerts, S. Vermeire, G. D'Haens, 2008, Gastroenterology.

Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis

P. Rutgeerts, S. Vermeire, A. Gils, 2014, Alimentary pharmacology & therapeutics.

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease

P. Rutgeerts, S. Vermeire, G. D'Haens, 2007, Gut.

Short-term response to infliximab in ulcerative colitis and pouchitis: Results from a single-center experience

P. Rutgeerts, S. Vermeire, M. Ferrante, 2006 .

Safety and efficacy of a novel IV targeted pegylated liposomal prednisolone product (Nanocort): results from a phase 2a study in patients with active ulcerative colitis

P. Rutgeerts, S. Vermeire, M. Ferrante, 2016 .

Mo1880 Mucosal Healing and Dysplasia Surveillance in a Large Referral Center Cohort of Patients With Crohn's Disease and Ulcerative Colitis Treated With Vedolizumab

P. Rutgeerts, S. Vermeire, M. Ferrante, 2016 .

W1132 A 3-Week Course of 80 Mg Weekly Administered Adalimumab As a Rescue Therapy for Patients with Crohn's Disease Who Lost Response to 40 Mg Weekly: Relationship with Adalimumab Trough Serum Levels

P. Rutgeerts, S. Vermeire, M. Ferrante, 2008 .

Long-term outcome after infliximab for refractory ulcerative colitis.

K. Van Steen, P. Rutgeerts, S. Vermeire, 2008, Journal of Crohn's & colitis.

A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis.

P. Rutgeerts, M. Noman, I. Aerden, 2003 .

Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

An Carbonez, Paul Rutgeerts, P. Rutgeerts, 2003, The New England journal of medicine.

Tolerability of Shortened Infliximab Infusion Times in Patients With Inflammatory Bowel Diseases: A Single-Center Cohort Study

P. Rutgeerts, S. Vermeire, M. Ferrante, 2011, The American Journal of Gastroenterology.

A Pilot Study on the Use of the Humanized Anti–Interleukin-2 Receptor Antibody Daclizumab in Active Ulcerative Colitis

P. Rutgeerts, M. Noman, I. Aerden, 2003, American Journal of Gastroenterology.

Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial.

P. Rutgeerts, S. Vermeire, G. D'Haens, 2008, Gastroenterology.

Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis.

P. Rutgeerts, S. Vermeire, G. D'Haens, 2003, Gastroenterology.

Predictors of early response to infliximab in patients with ulcerative colitis

Konstantinos H. Katsanos, Paul Rutgeerts, P. Rutgeerts, 2007, Inflammatory bowel diseases.

UEG Week 2016 Oral Presentations

A. Gils, M. Ferrante, M. Noman, 2016 .

Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases

S. Vermeire, A. Gils, M. Ferrante, 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease

P. Rutgeerts, S. Vermeire, M. Ferrante, 2005, Alimentary pharmacology & therapeutics.

LONG-TERM OUTCOME OF TREATMENT WITH INFLIXIMAB IN 440 CROHN'S DISEASE PATIENTS: RESULTS FROM A SINGLE CENTER COHORT

P. Rutgeerts, S. Vermeire, M. Ferrante, 2007 .

O08 Concomitant Immunosuppression Does Not Impact on the Outcome Of Maintenance Infliximab Therapy in Crohn's Disease: Final Results of the Imid Trial

P. Rutgeerts, S. Vermeire, G. D'Haens, 2007 .

Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab†

P. Rutgeerts, S. Vermeire, M. Noman, 2010, Inflammatory bowel diseases.

Mucosal healing predicts long‐term outcome of maintenance therapy with infliximab in Crohn's disease

P. Rutgeerts, S. Vermeire, M. Ferrante, 2009, Inflammatory bowel diseases.

P088 COLECTOMY RATES AFTER INFLIXIMAB FOR REFRACTORY ULCERATIVE COLITIS AND PREDICTIVE FACTORS

P. Rutgeerts, S. Vermeire, M. Ferrante, 2007 .

Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double-blind controlled randomized trial

P. Rutgeerts, S. Vermeire, M. Noman, 2007 .

P262 Patients with refractory pouchitis receiving adalimumab may avoid permanent ileostomy

P. Rutgeerts, S. Vermeire, M. Ferrante, 2012 .

Octreotide for the treatment of diarrhoea in patients with ileal pouch anal anastomosis: a placebo‐controlled crossover study

P. Rutgeerts, S. Vermeire, M. Ferrante, 2012, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

O09 Severe Postoperative Recurrence of Crohn's Disease (CD) Is Significantly Reduced With Combination Therapy Metronidazole + Azathioprine: A Double-Blind Controlled Randomized Trial

P. Rutgeerts, S. Vermeire, G. D'Haens, 2007 .

Consecutive Fecal Calprotectin Measurements to Predict Relapse in Patients with Ulcerative Colitis Receiving Infliximab Maintenance Therapy

J. Belaiche, O. Dewit, D. Franchimont, 2013, Inflammatory bowel diseases.

Characteristics of Skin Lesions Associated With AntiTumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease

P. Rutgeerts, I. Cleynen, J. J. van den Oord, 2015, Annals of Internal Medicine.

IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab

P. Rutgeerts, S. Vermeire, F. Baert, 2009, Pharmacogenetics and genomics.

P005 Restoration of Foxp3 regulatory T cells in blood correlates with clinical response to anti-TNF therapy for IBD

P. Rutgeerts, S. Vermeire, M. Ferrante, 2012 .

Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study.

P. Rutgeerts, S. Vermeire, M. Noman, 2010, Journal of Crohn's & colitis.